Nintedanib Sandoz (Nintedanib)

Nintedanib inhibits several receptor tyrosine kinases, including VEGFR, PDGFR and FGFR. By blocking these signals it reduces fibroblast proliferation, angiogenesis and the formation of fibrotic tissue, which helps preserve lung function and can limit tumor blood supply when used with chemotherapy.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for nintedanib in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nintedanib differs from other antifibrotics such as pirfenidone by targeting a broader range of tyrosine kinases (VEGFR, PDGFR, FGFR). This multi‑target approach may offer benefits in certain fibrotic lung diseases and in combination cancer regimens, though individual response and tolerability vary.

Nintedanib Sandoz should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

The medication is taken orally, usually as a tablet or capsule, with water. It is commonly taken twice daily with food to reduce gastrointestinal discomfort, but patients should follow the exact instructions provided by their healthcare professional.

Serious adverse events include hepatotoxicity (significant liver injury), severe bleeding, and opportunistic infections. Patients should be monitored regularly for liver enzyme elevations, signs of bleeding, and any unusual infections, and they should report these promptly to their physician.

Nintedanib is contraindicated in patients with severe hepatic impairment, active bleeding disorders, or those receiving strong CYP3A4 inducers that would markedly reduce drug exposure. Caution is also advised for individuals with moderate renal impairment or uncontrolled cardiovascular disease.